阿尔戈斯一号，第二视力公司的第一个试验雏形，实际上用的是一个原本是为耳蜗植入设备设计的信号处理器。
The Argus I, Second Sight's first experimental prototype, actually used a signal processor originally designed for cochlear implants.
他们已经在实验室中培育出rpe细胞薄片，而且证明这可以使白鼠和猪恢复视力。他们希望明年初可以进行第一次的人体试验。
They have grown tiny sheets of RPE cells in the lab and have shown these can restore vision in rats and pigs.
远望未来，第二视力公司已经准备好对阿尔戈斯三号在动物身上展开试验，阿尔戈斯三号预计会具有好几百个电极。
Looking further ahead, Second Sight is already conducting animal trials on the Argus III, which is expected to have several hundred electrodes.
在6名盲人试用人造视网膜雏形机后视力成功恢复之后，针对新型视网膜修复术的试验将在不久将来进行。
Trials of the new retinal prosthesis will begin shortly, following the success of a prototype that has enabled six blind people to see again.
先前利用动物模型的试验表明，这一基因治疗能保护及改善视力。
Previous work using animal models has demonstrated that this gene therapy can improve and preserve vision.
试验计划将集中在六个关键的外科领域：需要麻醉的心脏病、癌症、神经病学、视力、脊柱畸形和牙科治疗。
The pilot project will focus on six key surgical areas: cardiac, cancer, neurology, sight, spinal deformity, and dental treatment requiring anaesthesia.
在这些试验中，原先患有该病的狗的视力得到恢复，它们能够毫无困难的穿越迷宫，而且在治疗之前它们也无法做到这一点。
During trials, the vision of dogs with the defect was restored to the extent that they were able to walk through a maze without difficulty; something they could not do before the treatment.
检查、记录其视力、眼压、房角图，对比二小时暗室低头试验前后高低眼压变动下房角变化情况。
We examined and recorded their visual acuities, intraocular pressures, prone head test in dark room for 2 hours (PHT) and the gonioscopic examination under high ocular pressures.
并没有任何试验提出有关平均视力、房水黑色素颗粒、成本或生活品质结果的数据。
No trial reported data related to mean visual acuity, aqueous melanin granules, costs, or quality of life outcomes.
目前没有强而有力的试验可以测量学校视力筛检的好处。
At present there are no robust trials available that allow the benefits of school vision screening to be measured.
因此，很明显地需要在各种机构执行规划良好的随机对照试验，以测量视力筛检可能的好处与害处。
There is, therefore, clearly a need for well-planned randomised controlled trials to be undertaken in various settings so that the potential benefits and harms of vision screening can be measured.
试验的研究者应该扩大纳入受试者标准，包括高度近视患者，并且应评估视力、屈光、上皮愈合时间、疼痛评分和不良事件。
Trial investigators should expand enrollment criteria to include participants with high myopia and should evaluate visual acuity, refraction, epithelial healing time, pain scores, and adverse events.
试验的参与者有中央dmo及中度视力丧失。
Participants in the trials had central DMO and moderate vision loss.
因为实证资料不足，无法断定视力筛检计划没有利益，即该项介入措施尚未经过严谨的研究试验。
The absence of such evidence cannot be taken to mean that vision screening is not beneficial; simply that this intervention has not yet been tested in robust trials.
现行对弱视的视力筛检计划，还没有被随机对照试验的临床实验证实其功效。
The lack of data from randomised controlled trials makes it difficult to analyse the impact of existing screening programmes on the prevalence of amblyopia.
现行对弱视的视力筛检计划，还没有被随机对照试验的临床实验证实其功效。
The lack of data from randomised controlled trials makes it difficult to analyse the impact of existing screening programmes on the prevalence of amblyopia.
应用推荐